重组人脑利钠肽与左西孟旦联合治疗难治性心衰的临床疗效及对心功能的影响研究  

Clinical efficacy of recombinant human brain natriuretic peptide combined with levosimendan in the treatment of refractory heart failure and its impact on cardiac function

作　　者：张勇[1] ZHANG Yong(Department of Cardiology,People's Hospital of Zoucheng City,Zoucheng 273500,China)

机构地区：[1]山东省邹城市人民医院心内科,273500

出　　处：《中国实用医药》2024年第20期106-109,共4页China Practical Medicine

摘　　要：目的探讨重组人脑利钠肽与左西孟旦联合治疗难治性心力衰竭(心衰)的临床疗效及对心功能的影响。方法选取80例难治性心衰患者,采取随机分组的形式将患者分为研究组和对照组,每组40例。对照组患者采用常规的治疗方法,研究组基于对照组添加注射用重组人脑利钠肽。比较两组患者的临床疗效,治疗前后的血管内皮功能指标[一氧化氮(NO)、内皮素-1(ET-1)],不良反应发生情况。结果研究组的治疗总有效率为80.00%,显著高于对照组的60.00%,存在统计学差异(P<0.05)。治疗前,两组患者的NO、ET-1比较,差异不具有统计学意义(P>0.05);治疗后,两组患者的NO均较本组治疗前升高,ET-1均较本组治疗前降低,且研究组NO(77.91±7.64)μmol/L高于对照组的(68.35±6.42)μmol/L,ET-1(38.29±4.71)ng/L低于对照组的(44.19±5.37)ng/L,存在统计学差异(P<0.05)。研究组不良反应发生率为12.50%,对照组为10.00%;两组的不良反应发生率比较差异不具有统计学意义(P>0.05)。结论重组人脑利钠肽联合左西孟旦治疗难治性心衰展现了显著的临床疗效,有效改善患者的心功能,治疗后的积极结果为难治性心衰的管理提供了新的思路,然而仍需进一步大规模研究验证其长期效果和安全性,这一治疗策略的潜在价值为难治性心衰患者的康复和生活质量提供了有益的启示。Objective To explore the clinical efficacy of recombinant human brain natriuretic peptide combined with levosimendan in the treatment of refractory heart failure and its impact on cardiac function.Methods 80 patients with refractory heart failure were selected and randomly divided into a study group and a control group,with 40 patients in each group.The control group was treated with conventional methods,and the study group was treated with levosimendan on the basis of the control group.The clinical efficacy,endothelial function indicators[nitric oxide(NO),endothelin-1(ET-1)]before and after treatment and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the study group was 80.00%,which was significantly higher than 60.00%of the control group(P<0.05).Before treatment,there was no significant difference in NO and ET-1 between the two groups(P>0.05).After treatment,NO in both groups was higher than that before treatment,and ET-1 was lower than that before treatment;the study group had higher NO of(77.91±7.64)μmol/L than(68.35±6.42)μmol/L in the control group,and lower ET-1 of(38.29±4.71)ng/L than(44.19±5.37)ng/L in the control group;there was statistical difference(P<0.05).The incidence of adverse reactions was 12.50%in the study group and 10.00%in the control group.There was no significant difference between the two groups(P>0.05).Conclusion The combination of recombinant human brain natriuretic peptide and levosimendan demonstrates significant clinical efficacy and effectively improves cardiac function in patients with refractory heart failure,and the positive results after treatment provide new ideas for the management of refractory heart failure.However,further large-scale research is still needed to verify its long-term effectiveness and safety.The potential value of this treatment strategy provides beneficial insights for the rehabilitation and quality of life of heart failure patients.

关 键 词：重组人脑利钠肽 左西孟旦 难治性心力衰竭 临床疗效 心功能 

分 类 号：R541.6[医药卫生—心血管疾病]